RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced the appointment of Jan
Hillson, M.D., as Senior Vice President of Clinical
Development. Dr. Hillson bolsters the Company's clinical
development leadership group with significant experience in all
phases of clinical development across various autoimmune disorders,
including systemic lupus erythematosus, which is the lead target
indication for PRV-3279, a DART® (bispecific antibody-based
molecule) targeting the B cell surface proteins CD32B and
CD79B.
"Jan will be making an immediate impact as our medical lead for
the PREVAIL-2 study, where she brings significant experience in the
treatment of systemic lupus erythematosus patients," stated
Eleanor Ramos, M.D., Chief Medical
Officer, Provention Bio. "Given Jan's immune-focused drug
development track record of successfully advancing novel treatments
to patients, she also further broadens our capabilities to identify
additional product candidates to intercept autoimmune diseases with
significant unmet medical need."
Dr. Hillson brings over two decades of experience in academic
research, patient care, teaching and directing strategy and
operations of clinical research and translational medicine
programs. Dr. Hillson was most recently Senior Vice President,
Clinical Development at Alpine Immune Sciences. Dr. Hillson also
served as Senior Vice President of Clinical and Translational
Research at ChemoCentryx. Dr. Hillson additionally held roles of
increasing responsibility at Momenta Pharmaceuticals, ZymoGenetics,
Bristol Myers Squibb and Xcyte Therapies. Dr. Hillson played
significant roles in the advancement of nipocalimab (M281), a
clinically validated, best-in-class anti-FcRn antibody and the
Phase 3 development of avacopan, which was recently approved for
ANCA-associated vasculitis. Prior to joining industry, Dr. Hillson
was a member of the clinical faculty of Harvard Medical School, Assistant Professor at the
University of Washington, and Division
Head of Rheumatology at Virginia Mason Medical Center. Dr. Hillson
currently serves on the board of directors at Eledon
Pharmaceuticals.
Dr. Hillson received her M.D. from Stanford School of Medicine, an M.S. in
Environmental Engineering from the California
Institute of Technology, an M.S. in Marine Chemistry from
Scripps Institute of Oceanography, and
a B.S. from Michigan State
University.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company focused on advancing the development of investigational
therapies that may intercept and prevent debilitating and
life-threatening immune-mediated disease. The Company's pipeline
includes clinical-stage product candidates that have demonstrated
in pre-clinical or clinical studies proof-of-mechanism and/or
proof-of-concept in autoimmune diseases, including type 1 diabetes,
celiac disease and lupus. Visit www.ProventionBio.com for more
information and follow us on Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc. uses its
website, www.proventionbio.com, as a means of disclosing
material nonpublic information and for complying with its
disclosure obligations under Regulation F.D. Such disclosures will
be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Forward Looking Statement:
Certain statements in this press release are forward-looking,
including but not limited to, statements relating to our product
pipeline, including our investigational product PRV-3279 and its
potential safety and efficacy in systematic lupus erythematosus,
the potential impact Dr. Hillson on the Company's capabilities and
our growth as a company. These statements may be identified by the
use of forward-looking words such as "will," "may," "believe," and
"expect," among others. These forward-looking statements are based
on the Company's current expectations and actual results could
differ materially. There are a number of factors that could cause
actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, risks related execution and results of clinical trial
and product development efforts, regulatory decisions relating to
our product candidates, the potential impacts of COVID-19 on our
business and financial results; changes in law, regulations, or
interpretations and enforcement of regulatory
guidance; uncertainties of patent protection and litigation;
the Company's dependence upon third parties; substantial
competition in the highly competitive pharmaceutical industry,
including for highly qualified personnel; risks related to
integrating new personnel into the Company; the Company's need for
additional financing and the risks listed under "Risk Factors" in
the Company's quarterly report on Form 10-Q for the quarter
ended September 30, 2021 and any subsequent filings with the
Securities and Exchange Commission. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval and commercialization of new products.
Provention does not undertake an obligation to update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
applicable law. The information set forth herein speaks only as of
the date hereof.
Investor Contacts:
Robert
Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
Sam Martin, Argot Partners
proventionbio@argotpartners.com
212-600-1902
Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/provention-bio-appoints-jan-hillson-md-as-senior-vice-president-of-clinical-development-301425997.html
SOURCE Provention Bio, Inc.